Pilot Evaluation of a New Galyfilcon A Contact Lens Compared to a Marketed Galyfilcon A Contact Lens
NCT ID: NCT01094730
Last Updated: 2018-06-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
185 participants
INTERVENTIONAL
2010-02-01
2010-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dispensing Evaluation of a Galyfilcon A Prototype Lens and a Marketed Contact Lens
NCT01180985
Dispensing Evaluation of a Prototype Contact Lens and a Marketed Contact Lens
NCT01094743
Non-Dispensing Evaluation of an Investigational Galyfilcon A Soft Contact Lens
NCT01054807
Evaluation of Enfilcon A Soft Contact Lens When Compared to Galyfilcon A Soft Contact Lens
NCT01706770
Pilot Evaluation of a New Galyfilcon A Lens Prototype and Enfilcon A Lens
NCT01192542
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
galyfilcon A prototype/marketed galyfilcon A
The galyfilcon A prototype lens worn daily for 12-16 days during the first period then the marketed galyfilcon A lens worn daily for 12-16 days during the second period.
galyfilcon A prototype lens
Experimental silicone hydrogel contact lens
marketed galyfilcon A lens
Marketed silicone hydrogel contact lens.
marketed galyfilcon A/galyfilcon A prototype
The marketed galyfilcon A lens worn daily for 12-16 days during the first period then the galyfilcon A prototype lens worn daily for 12-16 days during the second period; during each period.
galyfilcon A prototype lens
Experimental silicone hydrogel contact lens
marketed galyfilcon A lens
Marketed silicone hydrogel contact lens.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
galyfilcon A prototype lens
Experimental silicone hydrogel contact lens
marketed galyfilcon A lens
Marketed silicone hydrogel contact lens.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of daily wear (DW) for a minimum of 1 month prior to the study) and willing to wear the study lenses on a daily wear basis (defined as a minimum of 6 hours of wear per day at least five days of the week) for the duration of the study.
* The subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and - 9.00D.
* Any cylinder power must be ≤ -0.75D.
* The subject must have visual acuity best correctable to 20/25+3 or better for each eye.
* The subject must read and sign the Statement of Informed Consent.
* The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
Exclusion Criteria
* Systemic disease or use of medication which might interfere with contact lens wear.
* Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
* Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear.
* Any ocular infection.
* Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
* Pregnancy or lactation.
* Diabetes.
* Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease (e.g. HIV).
* Habitual contact lens type is toric, multifocal, or is worn as extended wear.
18 Years
39 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cupertino, California, United States
Huntington Beach, California, United States
Los Angeles, California, United States
Pismo Beach, California, United States
Jacksonville, Florida, United States
Orlando, Florida, United States
East Lansing, Michigan, United States
Columbus, Ohio, United States
Amarillo, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-1636AY
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.